Table 3.

Adverse events summary for patients ≥ 65 and < 65 years

Adverse events, n (%)	≥ 65 years		p value	< 65 years		p value	Treatment-by-age subgroup interaction
	LY IGlar N = 112	SA IGlar N = 102		LY IGlar N = 264	SA IGlar N = 278
Patients with ≥ 1 TEAE	63 (56.3)	56 (54.9)	0.843	133 (50.4)	128 (46.0)	0.313	0.714
Special topic assessmenta	5 (4.5)	7 (6.9)	0.447	16 (6.1)	20 (7.2)	0.597	0.695
Injection site reactions	4 (3.6)	1 (1.0)	0.211	9 (3.4)	8 (2.9)	0.723	0.337
Patients with ≥ 1 SAE	8 (7.1)	11 (10.8)	0.351	7 (2.7)	7 (2.5)	0.922	0.487

INT interaction, LY IGlar LY2963016 insulin glargine, N number of evaluable patients, n number of patients with TEAE, SAE serious adverse event, SA IGlar insulin glargine, TEAE treatment-emergent adverse event

^aCategories of adverse events also include special topic assessment of adverse (allergic) events, injection site reactions, and SAEs though overall events are less than 5%